건조 혈반 채취 카드 시장 : 제품 유형, 기술, 검체 유형, 용도, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Dried Blood Spot Collection Cards Market is projected to grow by USD 595.64 million at a CAGR of 5.64% by 2032.

Dried Blood Spot Collection Cards Market Introduction

Dried blood spot collection cards are moving from a specialized neonatal screening tool to a broader decentralized sampling platform for newborn screening, infectious disease surveillance, therapeutic drug monitoring, toxicology, genomics, and population health research. The core value proposition is well established: capillary blood can be collected on validated filter paper, dried, transported with reduced cold-chain dependence, and analyzed using immunoassay, PCR, and mass spectrometry workflows.

Demand is supported by verified public health use cases, including newborn screening programs coordinated through national and regional health systems and biomonitoring applications referenced by public health agencies such as the CDC. Industry participants are differentiating through card material consistency, sample traceability, automation compatibility, and compliance with ISO, CLSI, FDA, and laboratory quality requirements.

Transformative Shifts in the DBS Card Landscape

The dried blood spot collection cards landscape is being reshaped by the shift from centralized phlebotomy-dependent testing toward home, community, and low-volume sampling models. This transition gained momentum as healthcare systems expanded remote care, epidemiological surveillance, and patient-centric clinical trial designs.

A second structural shift is the convergence of DBS cards with high-sensitivity analytical platforms. Liquid chromatography-tandem mass spectrometry, molecular diagnostics, and multiplex assays have improved the utility of small-volume dried specimens. At the same time, manufacturers face higher expectations for lot-to-lot uniformity, contamination control, humidity protection, barcoding, and chain-of-custody documentation.

Cumulative Impact of Artificial Intelligence on DBS Workflows

Artificial intelligence is adding value across the DBS workflow, but its impact is strongest when paired with validated laboratory methods. AI-enabled image analysis can support spot quality assessment by identifying underfilled, oversaturated, layered, or contaminated samples before testing, helping laboratories reduce rejection rates and recollection burden.

AI also supports demand planning, logistics optimization, and automated interpretation of high-throughput assay data. In regulated environments, however, AI must be governed by audit trails, bias controls, cybersecurity safeguards, and documented validation. The competitive advantage will come from combining DBS card reliability with transparent, compliant analytics rather than replacing laboratory expertise.

Key Regional Insights for Dried Blood Spot Collection Cards

Asia-Pacific is expanding through newborn screening modernization, large population health initiatives, and growing domestic diagnostics manufacturing in China, India, Japan, South Korea, and Australia. The region's adoption is supported by national screening expansion, infectious disease monitoring, and the operational need for sample formats that can move efficiently across dense urban systems and hard-to-reach communities. North America remains a high-value region because the United States and Canada have mature newborn screening systems, strong clinical laboratory infrastructure, established biobanking capabilities, and broad adoption of decentralized clinical research models.

Latin America shows rising use in public health surveillance and access-focused diagnostics, with Brazil and Mexico acting as important adoption centers for neonatal screening, infectious disease monitoring, and community-based sample collection. Europe benefits from established screening programs, GDPR-driven data governance, accredited laboratory networks, and quality-oriented procurement that prioritizes validated substrates and documented traceability. The Middle East is building capacity through national genomics, preventive health programs, and laboratory modernization, while Africa demonstrates strong relevance for DBS cards in HIV, metabolic disease, maternal and child health, and remote population testing where transport simplicity and ambient stability are critical.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is shaped by expanding universal health coverage, neonatal screening upgrades, infectious disease surveillance, and the need for sampling formats that work across island, border, and rural geographies. GCC countries are investing in preventive care, genomics, rare disease screening, and high-specification laboratory infrastructure, creating opportunities for premium dried blood spot collection cards with traceability, validated performance, and compliance features.

The European Union emphasizes harmonized quality systems, privacy-by-design data handling, CE-aligned diagnostic compliance, and validated clinical performance across laboratory networks. BRICS markets combine large patient populations with domestic manufacturing priorities and public health scale, making affordability, quality assurance, and scalable production essential. G7 countries lead in regulated clinical research, biomarker validation, newborn screening optimization, and automation adoption, while NATO-aligned procurement environments place additional emphasis on resilient medical supply chains, biosurveillance readiness, and secure sample traceability.

Key Country Insights in Major DBS Card Markets

The United States leads through state newborn screening programs, CLIA-certified laboratories, clinical trial decentralization, and established public health surveillance capabilities, while Canada emphasizes public health integration, provincial screening programs, and equitable access across remote and northern communities. Mexico and Brazil present access-driven opportunities in neonatal screening, infectious disease monitoring, and decentralized sample collection. The United Kingdom, Germany, France, Italy, and Spain rely on mature clinical laboratory networks, strict quality requirements, and regulated diagnostic pathways, while Russia's large geography supports interest in durable sampling formats that reduce dependency on complex transport conditions.

China and India offer scale, local manufacturing momentum, expanding preventive care programs, and increasing use of molecular and mass spectrometry-based testing. Japan, South Korea, and Australia are advanced markets for precision diagnostics, quality-controlled sample handling, newborn screening refinement, and research applications. Across these countries, adoption is strongest where dried blood spot collection cards reduce collection burden, simplify logistics, support validated downstream analysis, and align with national laboratory quality standards.

Actionable Recommendations for DBS Industry Leaders

Industry leaders should prioritize validated card performance, robust packaging, and compatibility with automated punching, extraction, and digital tracking systems. Procurement decisions increasingly favor suppliers that can prove lot consistency, analyte stability, contamination control, humidity protection, and regulatory documentation.

Organizations should build partnerships with clinical laboratories, public health agencies, and decentralized trial operators to align card design with real-world workflows. Investments in barcoding, sample-quality imaging, humidity indicators, tamper-evident packaging, and AI-supported logistics can improve operational reliability. Regional strategies should balance premium regulated markets with cost-efficient offerings for high-volume public health programs.

Research Methodology for the DBS Card Executive Summary

This executive summary is developed using secondary research from public health agencies, regulatory guidance, standards organizations, peer-reviewed literature, clinical laboratory practice references, and publicly available product documentation. Key sources considered include newborn screening frameworks, CDC dried blood spot applications, CLSI guidance on blood collection quality, FDA expectations for regulated products, ISO-aligned quality principles, and published evidence on DBS use in diagnostics, surveillance, and biomonitoring.

The methodology combines qualitative market assessment, regional policy review, technology trend mapping, and end-use evaluation across clinical diagnostics, research, public health, and pharmaceutical applications. Insights are validated by triangulating adoption drivers, regulatory constraints, laboratory workflow requirements, sample integrity considerations, and supply chain factors.

Conclusion: DBS Cards as a Scalable Sampling Platform

Dried blood spot collection cards are becoming a strategic component of decentralized diagnostics, newborn screening, and population health infrastructure. Their value lies in enabling small-volume sample collection, simplified transport, and scalable testing without eliminating the need for rigorous validation, standardized handling, and laboratory quality control.

Future adoption will depend on quality-controlled materials, regulatory readiness, automation compatibility, ambient sample stability, and digital sample traceability. Suppliers that combine proven card chemistry with workflow intelligence and regional market adaptation will be best positioned to address demand across clinical, research, and public health settings.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Dried Blood Spot Collection Cards Market, by Product Type

• 7.1. Filter Paper Cards
• 7.2. Polymer Coated Cards

8. Dried Blood Spot Collection Cards Market, by Technology

• 8.1. Advanced DBS Cards
• 8.2. Standard DBS Cards

9. Dried Blood Spot Collection Cards Market, by Sample Type

• 9.1. Plasma Spots
• 9.2. Serum Spots
• 9.3. Whole Blood Spots

10. Dried Blood Spot Collection Cards Market, by Application

• 10.1. Clinical Diagnostics
• 10.2. Disease Surveillance
• 10.3. Forensic Toxicology
• 10.4. Newborn Screening
  • 10.4.1. Congenital Hypothyroidism
  • 10.4.2. Cystic Fibrosis Screening
  • 10.4.3. Phenylketonuria
• 10.5. Therapeutic Drug Monitoring

11. Dried Blood Spot Collection Cards Market, by End User

• 11.1. Diagnostic Laboratories
• 11.2. Home Care Settings
• 11.3. Hospitals & Clinics
• 11.4. Research Institutes

12. Dried Blood Spot Collection Cards Market, by Distribution Channel

• 12.1. Direct Sales
• 12.2. Distributors & Wholesalers

13. Dried Blood Spot Collection Cards Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Dried Blood Spot Collection Cards Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Dried Blood Spot Collection Cards Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. F. Hoffmann-La Roche Ltd.
• 17.2. Merck KGaA
• 17.3. QIAGEN N.V.
• 17.4. Ahlstrom Oyj
• 17.5. Shimadzu Corporation
• 17.6. Inotiv, Inc.
• 17.7. CENTOGENE GmbH
• 17.8. BioIVT LLC
• 17.9. Salimetrics, LLC.
• 17.10. Monobind Inc.
• 17.11. Eastern Business Forms, Inc
• 17.12. Capitainer AB
• 17.13. Chemie-Erzeugnisse und Adsorptionstechnik AG
• 17.14. ADVANTEC MFS, INC.
• 17.15. ARCHIMEDlife GmbH by amedes Holding GmbH
• 17.16. Cambrian Biotech Pvt. Ltd.
• 17.17. DBS System SA
• 17.18. Huachenyang (Shenzhen) Technology Co., Ltd
• 17.19. Kala Scientific INC.
• 17.20. OmegaQuant Analytics, LLC
• 17.21. RDA Spot Inc
• 17.22. Telimmune LLC
• 17.23. Tianjin Geneally Biotechnology Co., Ltd.